Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 47

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 47
---
 relating to, the Discontinuance and consult with the Purchaser, as the Purchaser 
 may reasonably request, to allow the Purchaser to monitor and provide input with respect to the direction and control of, any such material decisions or actions or developments.                                                                  |

| (b) | Without limiting the generality of the foregoing, the Company covenants and agrees that, during the Interim                                                                                                                                         
 Period, unless (i) the Purchaser shall otherwise agree to in writing (such prior written consent not to be unreasonably withheld, conditioned or delayed), (ii) expressly permitted (including as pertains to or arises out of, or in connection    
 with, any Permitted Disposition) or specifically contemplated by this Agreement and the Contemplated Transactions (including, for the avoidance of doubt, in connection with the Discontinuance), (iii) as required by any Contract, by Law or by a 
 Governmental Entity, or (iv) as set forth on Section 5.1(b) of the Disclosure Letter, the Company shall, and shall cause its Subsidiary to:                                                                                                         |

| (A) | not split, consolidate or reclassify any of its outstanding shares nor undertake any other capital 
 reorganization, nor reduce capital in respect of its outstanding shares;                           |

| (B) | not declare, set aside or pay any dividends on or make any other distributions on or in respect of its 
 outstanding shares;                                                                                    |

| (C) | not amend its articles of incorporation, by-laws or other comparable        
 organizational documents or the terms of any of its outstanding securities; |

| (D) | except for amendments to any existing Incentive Securities to facilitate the treatment of outstanding Incentive                                                                                                                                          
 Securities in accordance with the Discontinuance and the Plan of Arrangement, not issue, grant, deliver, sell, exchange, amend, modify, accelerate, pledge or otherwise subject to any Encumbrance (other than Permitted Encumbrances), or authorize any 
 such action in respect of, any securities of the Company (other than the issuance of Common Shares upon the exercise of currently outstanding Options or other Convertible Securities in accordance with their terms); more specifically (and without    |

- 25 -

| limiting the generality of the foregoing), not authorize, approve, agree to issue, issue or award any Incentive Securities under the Equity Incentive Plan or any other Convertible Securities; |

| (E) | not redeem, offer